Lucid Diagnostics (NASDAQ:LUCD) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.07) by 33.33 percent. This is a 20 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $1.474 million which missed the analyst consensus estimate of $1.943 million by 24.14 percent. This is a 26.74 percent increase over sales of $1.163 million the same period last year.